Drug Candidate for Treatment of Pain
Olorinab (APD371) is an oral, peripherally acting, highly selective, full agonist of the cannabinoid type 2 receptor (CB2). Olorinab is an internally discovered investigational drug candidate that Arena is exploring for development in several indications, with an initial focus on visceral pain in gastrointestinal disorders. This compound, through its selectivity for CB2, versus the cannabinoid type 1 receptor (CB1), was designed to provide pain relief while minimizing the risk of psychoactive adverse effects.
About IBS
Irritable bowel syndrome (IBS) is a common disorder of the gastrointestinal (GI) tract. Signs and symptoms include cramping, abdominal pain, bloating, gas, and predominant constipation (IBS-C) or diarrhea (IBS-D), or mixed (IBS-M). IBS is a chronic condition that needs to be managed long term. There are approximately 27 million patients in the United States with IBS, with approximately 80% reporting frequently recurring or continuous abdominal pain.
Status
| Drug Candidate | Disease Area | Target | Status | Retained Rights |
|---|---|---|---|---|
| Olorinab (APD371) | GI Pain | CB2 Agonist | Phase 2b | Worldwide |
| Drug Candidate | Olorinab (APD371) |
|---|---|
| Disease Area | GI Pain |
| Target | CB2 Agonist |
| Status | Phase 2b ongoing |
| Retained Rights | Worldwide |
Olorinab (APD371) has not been approved by the US Food and Drug Administration or any other regulatory agency.
Last updated as of 8/7/19